"Cross Reactions" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
| Descriptor ID |
D003429
|
| MeSH Number(s) |
G12.122.281
|
| Concept/Terms |
Cross Reactions- Cross Reactions
- Cross Reaction
- Reaction, Cross
- Reactions, Cross
|
Below are MeSH descriptors whose meaning is more general than "Cross Reactions".
Below are MeSH descriptors whose meaning is more specific than "Cross Reactions".
This graph shows the total number of publications written about "Cross Reactions" by people in this website by year, and whether "Cross Reactions" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 0 | 3 | 3 |
| 2011 | 0 | 3 | 3 |
| 2013 | 1 | 1 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2021 | 0 | 3 | 3 |
| 2022 | 2 | 1 | 3 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cross Reactions" by people in Profiles.
-
SARS-CoV-2 BA.4/5 infection triggers more cross-reactive Fc?RIIIa signaling and neutralization than BA.1, in the context of hybrid immunity. J Virol. 2024 Jul 23; 98(7):e0067824.
-
Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants. J Virol. 2022 08 10; 96(15):e0055822.
-
T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature. 2022 03; 603(7901):488-492.
-
SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity. Cell Rep Med. 2022 02 15; 3(2):100510.
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 09; 8(9):e568-e580.
-
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep Med. 2021 06 15; 2(6):100313.
-
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). N Engl J Med. 2021 06 03; 384(22):2161-2163.
-
New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. J Virol. 2016 01 01; 90(1):76-91.
-
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. J Thromb Haemost. 2015 Nov; 13(11):1989-98.
-
HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell Host Microbe. 2014 Aug 13; 16(2):215-226.